Your browser is no longer supported. Please, upgrade your browser.
BMRN BioMarin Pharmaceutical Inc. monthly Stock Chart
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-1.08 Insider Own0.50% Shs Outstand160.34M Perf Week1.09%
Market Cap21.94B Forward P/E- EPS next Y-1.51 Insider Trans-29.02% Shs Float160.08M Perf Month10.56%
Income-163.40M PEG- EPS next Q-0.53 Inst Own99.40% Short Float3.18% Perf Quarter13.67%
Sales802.80M P/S27.33 EPS this Y28.10% Inst Trans-0.01% Short Ratio4.02 Perf Half Y51.37%
Book/sh15.39 P/B8.89 EPS next Y29.40% ROA-6.00% Target Price147.06 Perf Year112.88%
Cash/sh6.29 P/C21.75 EPS next 5Y25.00% ROE-9.40% 52W Range55.36 - 141.51 Perf YTD51.37%
Dividend- P/FCF- EPS past 5Y37.13% ROI-4.70% 52W High-1.43% Beta0.57
Dividend %- Quick Ratio4.30 Sales past 5Y18.30% Gross Margin82.60% 52W Low151.95% ATR3.97
Employees1681 Current Ratio5.00 Sales Q/Q34.10% Oper. Margin-25.20% RSI (14)67.16 Volatility2.46% 2.78%
OptionableYes Debt/Eq0.27 EPS Q/Q-65.40% Profit Margin-20.40% Rel Volume0.93 Prev Close136.84
ShortableYes LT Debt/Eq0.27 EarningsJul 30 AMC Payout- Avg Volume1.27M Price139.48
Recom1.90 SMA207.00% SMA5011.37% SMA20035.59% Volume1,118,842 Change1.93%
Jun-19-15Downgrade Robert W. Baird Outperform → Neutral $125 → $133
Jun-18-15Reiterated Sun Trust Rbsn Humphrey Buy $151 → $170
Jun-18-15Reiterated RBC Capital Mkts Outperform $125 → $145
Jun-18-15Reiterated Piper Jaffray Overweight $123 → $147
Jun-18-15Reiterated Jefferies Buy $135 → $150
Jun-18-15Reiterated Deutsche Bank Buy $140 → $156
Jun-18-15Reiterated Canaccord Genuity Buy $115 → $150
Jun-05-15Initiated Barclays Overweight $150
May-27-15Reiterated JP Morgan Overweight $125 → $140
May-01-15Reiterated JP Morgan Overweight $120 → $125
Mar-27-15Reiterated UBS Buy $112 → $136
Mar-27-15Reiterated Deutsche Bank Buy $90 → $140
Dec-19-14Reiterated RBC Capital Mkts Outperform $103 → $110
Dec-11-14Reiterated UBS Buy $87 → $112
Nov-25-14Reiterated RBC Capital Mkts Outperform $87 → $103
Oct-24-14Reiterated RBC Capital Mkts Outperform $77 → $87
Feb-19-14Reiterated Barclays Equal Weight $73 → $76
Jan-14-14Reiterated Deutsche Bank Buy $75 → $85
Jan-10-14Downgrade Barclays Overweight → Equal Weight $75 → $73
Oct-25-13Reiterated Barclays Overweight $70 → $75
Jul-02-15 03:45PM  Dwarfism Drug Brings Mixed Emotions for Little People, Parents at Bloomberg
03:45PM  Dwarfism Drug Brings Mixed Emotions for Little People, Parents
09:30AM  The Zacks Analyst Blog Highlights: Celgene, Juno Therapeutics, Intercept, BioMarin and Sarepta - Press Releases
Jul-01-15 11:29AM  Biotech Stock Roundup: Juno-Celgene In Immunotherapy Deal, BioMarin/Sarepta DMD Drugs Progress - Analyst Blog
Jun-30-15 05:57PM  Should The Biotech Bubble Be Feared?
04:30PM  Sarepta Files Eteplirsen NDA, Secures $40M Debt Financing - Analyst Blog
04:25PM  BioMarin's NDA for DMD Drug Drisapersen Accepted by FDA - Analyst Blog
Jun-29-15 03:50PM  Sarepta CEO: Teamwork has been key to quick progress on Duchenne drug at bizjournals.com
10:18AM  BioMarin, Sarepta Muscular Dystrophy Drugs Progress at Investor's Business Daily
08:30AM  BioMarin Announces FDA Accepts Drisapersen NDA for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping GlobeNewswire
07:02AM  Sarepta Submits DMD Drug for FDA Approval Review at TheStreet
Jun-26-15 06:35PM  BioMarin DMD Drug Drisapersen Validated for EU Review - Analyst Blog
Jun-25-15 04:01PM  BioMarin Announces EMA Validates MAA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping GlobeNewswire
09:30AM  The Zacks Analyst Blog Highlights: BioMarin, Vical, Epizyme, Amgen and Medicines Co - Press Releases
Jun-24-15 08:44AM  Biotech Stock Roundup: BioMarin Jumps on Dwarfism Data, Vical Plunges on Vaccine Data - Analyst Blog
Jun-23-15 03:24PM  BioMarin CEO: Excited about dwarfism drug potential
06:00AM  5 Biotech Stocks to Trade for Gains at TheStreet
Jun-22-15 12:02PM  BioMarin Pharmaceutical (BMRN) Stock Is the 'Chart of the Day' at TheStreet
Jun-20-15 12:19AM  Charting the Market at Barrons.com
Jun-19-15 04:10PM  BioMarin Pharmaceutical Surges on Price Target Increase - Analyst Blog
03:19PM  Biotech to break out, buy these names: Analyst at CNBC
02:29PM  BioMarin: Too Expensive? at Barrons.com
01:41PM  Biotechs about to break out: Pro
08:50AM  Top Analyst Upgrades and Downgrades: BioMarin, BP, Micron, Vonage, Finisar, ConEd, Red Hat and More at 24/7 Wall St.
06:52AM  Biomarin Pharm downgraded by Robert W. Baird
Jun-18-15 07:35PM  Cramer Remix-Before strolling with Johnnie Walker at CNBC +12.18%
04:21PM  Daily Movers: Welcoming Fitbit; BioMarin Soars Again, While Oracle Slumps
03:32PM  Mid-Afternoon Market Update: BioMarin Pharmaceutical Jumps Following Announcement Of Positive BMN 111 Data; Jabil Circuit Shares Fall
02:55PM  Edited Transcript of BMRN conference call or presentation 17-Jun-15 8:30pm GMT
01:40PM  3 Drivers Supporting BioMarin
01:31PM  Mid-Day Market Update: Oracle Drops On Downbeat Results; Radius Health Shares Surge
12:08PM  BioMarin Pharmaceutical Inc. (BMRN) Surges But Is It A Good Stock To Buy Now? at Insider Monkey
11:22AM  BioMarin (BRMN) Stock Jumps on Dwarfism Treatment Trial at TheStreet
10:36AM  BioMarin Stock Hits High On Dwarfism Drug Success at Investor's Business Daily
10:31AM  BioMarin's Results Are In: What Do They Mean?
10:29AM  Jim Cramer -- BioMarin and Radius Health Deserve Today's Big Rally at TheStreet
10:22AM  Mid-Morning Market Update: Markets Open Higher; Kroger Earnings Beat Views
10:11AM  BioMarin Spikes on Drug Trial; Shares Hit New High at Barrons.com
09:27AM  Cramer's Mad Dash: BMRN & RDUS
08:55AM  Well soon find out if this gold rally is for real at MarketWatch
07:22AM  Study for treatment for dwarfism send BioMarin stock skyward
Jun-17-15 05:39PM  Pier 1, BioMarin, HomeAway & Oracle Lead Wednesday's After-Hours Movers
04:30PM  Biomarin Pharmaceutical Inc to Discuss Phase 2 Results with BMN 111 Call scheduled for 4:30 pm ET today
04:24PM  BioMarin spikes on positive drug study
04:01PM  BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study GlobeNewswire
Jun-16-15 06:00PM  Cramer: This stock could go up HUGE!
Jun-15-15 05:12PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of
10:44AM  Is BioMarin A Buy Ahead Of This Important Data Release?
08:30AM  BioMarin CEO Jean-Jacques Bienaime Awarded EY Entrepreneur Of The Year(R) 2015 Award in Northern California in Health and Life Sciences GlobeNewswire
08:23AM  Quartet of GSK cast-off drugs soar to a combined value of $5bn at Financial Times
Jun-12-15 08:19AM  Edited Transcript of BMRN presentation 11-Jun-15 3:00pm GMT
08:00AM  PTC Therapeutics and BioMarin Pharmaceutical to Host DMD Industry Symposium PR Newswire
Jun-09-15 04:25PM  BioMarin Seeks EU Approval for DMD Drug Drisapersen - Analyst Blog
Jun-08-15 08:30AM  BioMarin Submits Drisapersen MAA to EMA for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping GlobeNewswire
Jun-05-15 11:51AM  Why BioMarin Could Gain 23% at Barrons.com
07:26AM  Barclays: BioMarin Is A Buy, Sees $150/Share
05:02AM  Biotech Stock Mailbag: More Duchenne Drama, CAR-T Trouble, ASCO '15 Rewind at TheStreet
Jun-04-15 04:05PM  Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Goldman Sachs 36th Annual Global Healthcare Conference GlobeNewswire
May-29-15 11:51AM  This stock is no longer in the Top 20 most held at CNBC
May-28-15 05:40PM  Next billion dollar drug?
May-27-15 06:00PM  Hey Fed -- I've got something to say
08:20AM  Analyst Has 4 Top US Growth Stock Calls for This Week at 24/7 Wall St.
May-22-15 06:00PM  Cramer shuts down this market's haters
May-21-15 05:24PM  Biotech stock set to double
12:38AM  Sareptas Feast May Not Satisfy at The Wall Street Journal
May-20-15 08:59PM  Sarepta Gets FDA Green Light to Submit Application at Investopedia
05:14PM  Sarepta's Feast May Not Satisfy at The Wall Street Journal
May-19-15 04:42PM  FDA Tells Sarepta Therapeutics: Come on Down With Your DMD Drug! at TheStreet
May-10-15 11:00AM  These biotech names are ripe for mergers: Analysts at CNBC
May-07-15 08:09PM  10-Q for BioMarin Pharmaceutical, Inc. at Company Spotlight
08:38AM  BioMarin Pharmaceutical (BMRN): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
08:30AM  Why These 4 Biotech Stocks Could Be the Next Buyout Targets at 24/7 Wall St.
May-06-15 05:26PM  Biotech takeover targets +5.07%
10:24AM  Why BioMarin's New Drug Application is Good News for Sarepta Therapuetics at Barrons.com
10:07AM  Rare disease stocks fly on Alexion acquisition
09:20AM  Baird Upgrades Sarepta Therapeutics After Positive Signal That FDA Is Ready To Review
May-05-15 02:32PM  Sure, the Biotech Sector is Getting Hammered. Here's How to Take Advantage. at Barrons.com
11:41AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report
May-04-15 12:40PM  Integra LifeSciences Tops Q1 Earnings, Revenues; View Up - Analyst Blog
10:22AM  No, the Biotech Boom Isn't Over at Barrons.com
May-01-15 09:55AM  BioMarin Q1 Loss Narrower than Expected, '15 View Revised - Analyst Blog
08:54AM  BioMarin Management to Present at the Deutsche Bank 40th Annual Health Care Conference on May 6th; Bank of America Merrill Lynch 2015 Health Care Conference on May 13th; and, the UBS Global Healthcare Conference on May 19th at noodls
08:00AM  BioMarin Management to Present at the Deutsche Bank 40th Annual Health Care Conference on May 6th; Bank of America Merrill Lynch 2015 Health Care Conference on May 13th; and, the UBS Global Healthcare Conference on May 19th GlobeNewswire
05:11AM  BioMarin Pharmaceutical (BMRN) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
Apr-30-15 04:51PM  BioMarin reports 1Q loss
04:30PM  Biomarin Pharmaceutical Inc Earnings Call scheduled for 4:30 pm ET today
04:17PM  BioMarin Announces First Quarter 2015 Financial Results and Company Update at noodls
04:12PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:01PM  BioMarin Announces First Quarter 2015 Financial Results and Company Update GlobeNewswire
07:07AM  Q1 2015 Biomarin Pharmaceutical Inc Earnings Release - After Market Close
Apr-29-15 04:32PM  BioMarin Upgraded to Strong Buy, Is It in Your Portfolio? - Analyst Blog
01:55PM  Can Expedia (EXPE) Pull a Surprise this Earnings Season? - Analyst Blog
09:30AM  Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Apr-28-15 04:10PM  Will BioMarin (BMRN) Top Earnings Again on Vimzim Sales? - Analyst Blog
12:09PM  Here's What's Next as BioMarin Moves Closer to Duchenne Drug Approval at TheStreet
09:19AM  BioMarin Pharmaceutical (BRMN) Stock Rises After CEO Appears on Jim Cramer's 'Mad Money' at TheStreet
06:00AM  Jim Cramer's Top Takeaways: Intel, Restoration Hardware, BioMarin Pharmaceuticals at TheStreet
Apr-27-15 07:58PM  [video]Jim Cramer's 'Mad Money' Recap: Market Squall Making Me Seasick at TheStreet
07:10PM  Cramer Remix: My take on Apple's massive earnings at CNBC
04:59PM  Will United Therapeutics (UTHR) Miss This Earnings Season? - Analyst Blog
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including drisapersen, an exon-51 skipping compound for the treatment of Duchenne muscular dystrophy (DMD); pegvaliase, an enzyme substitution therapy for the treatment of PKU; reveglucosidase alfa, an enzyme replacement therapy for Pompe disease; talazoparib, an orally available poly-ADP ribose polymerase inhibitor for cancer treatment; BMN 111, a peptide therapeutic for achondroplasia treatment; BMN 044, BMN 045, and BMN 053 for DMD treatment; and cerliponase alfa for the treatment of late infantile neuronal ceroid lipofuscinosis. In addition, it develops preclinical product candidates for genetic and other metabolic diseases, such as BMN 270 and BMN 250. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. S.A. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerJun 05Sale122.301,649201,66928,229Jun 08 06:09 PM
FUCHS HENRY JEVP, Chief Medical OfficerJun 05Sale122.321,864228,00172,846Jun 08 06:06 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfJun 04Sale122.351,362166,64635,605Jun 08 05:43 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfJun 01Sale123.7637746,65738,455Jun 03 08:23 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerJun 01Sale124.163,945489,81131,679Jun 03 08:27 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 29Sale126.151,578199,06535,624Jun 03 08:27 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 26Sale126.551,625205,64739,245May 26 07:52 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 18Sale124.781,864232,58476,746May 19 07:21 PM
Davis George EricSVP, General CounselMay 18Sale125.262,558320,41569,226May 19 07:18 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 18Sale130.0034,0784,430,14041,507May 28 05:10 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 13Sale121.371,434174,03880,646May 14 06:54 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 11Sale121.642,869348,98883,646May 12 07:27 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 06Option Exercise33.9333,6311,141,21576,664May 08 05:49 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 06Sale119.1434,0194,053,04242,645May 08 05:49 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 01Option Exercise6.4623,218149,98856,476May 05 07:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 01Sale114.9823,2182,669,51733,258May 05 07:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 01Sale114.983,505402,992248,654May 05 07:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 01Option Exercise6.4622,546145,64755,804Apr 03 01:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 01Sale120.5322,5462,717,54633,258Apr 03 01:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 01Sale120.533,506422,590251,251Apr 03 01:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 20Sale126.401,000126,39633,258Mar 24 07:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 17Sale124.871,000124,86634,258Mar 18 08:02 PM
FUCHS HENRY JEVP, Chief Medical OfficerMar 16Option Exercise21.5140,000860,400129,950Mar 18 07:50 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 16Sale123.481,000123,47735,258Mar 18 08:02 PM
FUCHS HENRY JEVP, Chief Medical OfficerMar 16Sale123.5741,3155,105,16688,635Mar 18 07:50 PM
Davis George EricSVP, General CounselMar 13Option Exercise37.0815,000556,23988,846Mar 17 06:03 PM
Davis George EricSVP, General CounselMar 13Sale120.8715,0001,813,00273,846Mar 17 06:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 10Sale114.892,021232,20136,258Mar 11 06:32 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Option Exercise12.9915,000194,85057,279Mar 11 06:32 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 09Sale112.1319,0002,130,38338,279Mar 11 06:32 PM
BAFFI ROBERTEVP, Technical OperationsMar 05Option Exercise17.1114,051240,364123,751Mar 05 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 05Option Exercise12.9910,000129,90052,279Mar 05 08:20 PM
BAFFI ROBERTEVP, Technical OperationsMar 05Sale116.3714,0511,635,091109,700Mar 05 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 05Sale113.7010,0001,137,01642,279Mar 05 08:20 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 04Option Exercise9.865004,93043,695Mar 04 07:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 04Sale107.7191698,66042,279Mar 04 07:39 PM
LAPALME PIERREDirectorMar 03Option Exercise14.2420,000284,80050,150Mar 05 05:34 PM
Mueller BrianVP, Corporate ControllerMar 03Option Exercise28.237,000197,61015,800Mar 05 05:31 PM
Mueller BrianVP, Corporate ControllerMar 03Sale109.467,000766,2108,800Mar 05 05:31 PM
LAPALME PIERREDirectorMar 03Sale106.5720,0002,131,40030,150Mar 05 05:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 03Sale107.425,000537,097215,157Mar 04 07:39 PM
Davis George EricSVP, General CounselMar 02Option Exercise26.4923,000609,27087,246Mar 04 07:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 02Option Exercise12.993,00038,97046,195Mar 04 07:39 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 02Option Exercise39.0615,500605,43084,176Mar 04 07:48 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 02Sale107.0015,5001,658,50068,676Mar 04 07:48 PM
Davis George EricSVP, General CounselMar 02Sale108.3123,0002,491,02764,246Mar 04 07:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 02Sale107.963,000323,89343,195Mar 04 07:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 02Sale108.445,000542,195220,157Mar 04 07:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 09Sale94.142,000188,286225,157Jan 13 07:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Option Exercise12.993,00038,97046,195Dec 29 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Sale88.733,000266,19343,195Dec 29 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Sale88.732,000177,462227,157Dec 29 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 10Option Exercise12.992,00025,98045,195Dec 12 01:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 10Sale95.002,000190,00043,195Dec 12 01:51 PM
LEWIS ALANDirectorDec 04Option Exercise21.517,500161,32528,900Dec 08 06:50 PM
LEWIS ALANDirectorDec 04Sale89.907,500674,22521,400Dec 08 06:50 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 03Option Exercise38.5912,000463,08043,590Dec 05 05:26 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 03Sale91.0112,0001,092,16131,590Dec 05 05:26 PM
Mueller BrianVP, Corporate ControllerDec 02Option Exercise28.235,000141,1509,593Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerDec 02Sale91.825,000459,1004,593Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerDec 01Option Exercise20.986,950145,78511,543Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerDec 01Sale90.256,950627,2384,593Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerNov 26Sale88.973,400302,5084,593Dec 02 05:19 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 25Option Exercise12.992,00025,98045,195Nov 28 09:24 PM
Davis George EricSVP, General CounselNov 25Option Exercise26.4920,000529,80084,426Nov 28 09:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 25Sale90.002,000180,00043,195Nov 28 09:24 PM
Davis George EricSVP, General CounselNov 25Sale89.7520,0001,795,00064,426Nov 28 09:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 12Sale81.511,00081,513228,157Nov 14 02:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 10Option Exercise12.994,00051,96047,195Nov 12 07:07 PM
FUCHS HENRY JEVP, Chief Medical OfficerNov 10Option Exercise21.5120,000430,20096,550Nov 12 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 10Sale87.004,000348,00043,195Nov 12 07:07 PM
FUCHS HENRY JEVP, Chief Medical OfficerNov 10Sale86.5520,0001,730,98276,550Nov 12 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 03Sale85.333,000256,00243,195Nov 05 07:45 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfNov 03Sale83.54473,92631,590Nov 05 07:44 PM
BAFFI ROBERTEVP, Technical OperationsOct 30Option Exercise38.5929,9631,156,272129,163Oct 31 02:58 PM
Davis George EricSVP, General CounselOct 30Option Exercise26.4915,000397,35079,426Nov 03 07:21 PM
Davis George EricSVP, General CounselOct 30Sale83.2015,0001,247,93064,426Nov 03 07:21 PM
BAFFI ROBERTEVP, Technical OperationsOct 29Option Exercise33.7445,4621,533,721144,662Oct 31 02:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 24Option Exercise12.992,00025,98048,195Oct 28 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 24Sale80.002,000160,00046,195Oct 28 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 21Option Exercise12.992,00025,98048,195Oct 23 06:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 21Sale75.002,000150,00046,195Oct 23 06:34 PM
Davis George EricSVP, General CounselSep 19Option Exercise21.5117,536377,19981,962Sep 23 08:41 PM
Davis George EricSVP, General CounselSep 19Sale69.7517,5361,223,13664,426Sep 23 08:41 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 03Sale69.77181,25668,733Feb 10 12:57 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 02Option Exercise39.0616,000624,96084,676Sep 03 06:48 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 02Sale69.8316,0001,117,31468,676Sep 03 06:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 20Option Exercise12.995,00064,95051,195Aug 22 08:10 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 20Sale70.005,000350,00046,195Aug 22 08:10 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 05Option Exercise21.5110,000215,10086,550Aug 07 06:28 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 05Sale65.0010,000650,00076,550Aug 07 06:28 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerAug 01Sale61.762,229137,65268,676Aug 04 04:35 PM